Status:
COMPLETED
Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Methotrexate (MTX) is the first-line treatment of rheumatoid arthritis (RA). In case of MTX failure, it is discussed to start a Biologic Disease-modifying Antirheumatic Drug (bDMARDs) according to the...
Detailed Description
The assumption is the association between low methotrexate erythrocyte polyglutamate and low clinical response in rheumatoid arthritis patients treated with subcutaneous injectable methotrexate. Adher...
Eligibility Criteria
Inclusion
- Age \> 18 years and have social security affiliation.
- Patients followed in the Rheumatology Department at the hospital of St Etienne.
- Patients with rheumatoid arthritis and :
- Either Rheumatoid arthritis patients in remission (DAS 28\<2.6) with MTX treatment for at least 6months, and with a stable dose for 3months.
- Or patients with a High Disease Activity Rheumatoid Arthritis activity (DAS 28\>3.2) with MTX treatment (≥ 15 mg/weeks), taking MTX treatment for at least 6months with a stable subcutaneous weekly MTX injection (≥ 15 mg/weeks) treatment during the previous 3 months.
- Signed informed consent.
Exclusion
- Patients treated with another conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARD)
- Another diagnostic than rheumatoid arthritis
Key Trial Info
Start Date :
July 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03445871
Start Date
July 2 2018
End Date
May 28 2020
Last Update
August 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Saint Etienne
Saint-Etienne, France, 42100